Leukemia, Myelodysplasia, Transplantation
News
Upfront idelalisib carries high risk for acute liver toxicity
Idelalisib given as first-line therapy for patients with chronic lymphocytic leukemia carries a high risk of early fulminant hepatotoxicity...
Conference Coverage
ALL patients over-report their 6MP compliance, researchers say
Photo courtesy of ASH ORLANDO, FL—A study comparing subjective versus objective reporting of treatment compliance in patients with acute...
Conference Coverage
ASH: Rituximab add-on therapy ‘new standard’ in BCP-ALL
Adding rituximab to standard intensive chemotherapy significantly improved event-free survival in adults with Philadelphia-negative, CD20-positive...
Video
VIDEO: Midostaurin hits mark in FLT3-mutated AML
The oral multikinase inhibitor midostaurin improved overall survival by 23% when added to standard chemotherapy and given as maintenance therapy...
News
Cancer drug prices vary widely from country to country
Photo by Bill Branson The price of cancer drugs varies widely between European countries, Australia, and New Zealand, according to a study...
Conference Coverage
ASH: Genes tag increased risk for avascular necrosis in ALL patients under age 10
Key clinical point: Gene profiles can identify ALL patients under age 10 at increased risk for avascular necrosis. Major finding: In children...
Conference Coverage
ASH: Pill bottles flag noncompliance in patients on ALL maintenance
Key clinical point: Patients in first ALL remission may not be as adherent to 6MP maintenance therapy as they claim. Major finding: In all, 40.4%...
News
FDA approves generic imatinib
Photo by Steven Harbour The US Food and Drug Administration (FDA) has approved the use of imatinib mesylate, a generic version of Novartis’s...
Conference Coverage
ASH: Genes, induction response identify high risk childhood B-lymphoblastic leukemia patients with good outcomes
Key clinical point: Knowing which patients would not benefit from further intensification of their chemotherapy might spare them possible toxicity...
Conference Coverage
ASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancers
Key clinical point: Allogeneic anti-CD19 CAR T-cell therapy showed promise in a treatment approach for B-cell malignancies persisting after...
News
Combo could target LSCs, treat CML
Image by Difu Wu Researchers say they have identified a mechanism governing malignant reprogramming of progenitors into self-renewing leukemia...